{"url_path":"/sec/mtex/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1056358/0001437749-26-017043-index.html","accession_number":"0001437749-26-017043","cik":"0001056358","ticker":"MTEX","issuer_name":"MANNATECH INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1056358/0001437749-26-017043-index.html","primary_entity_key":"0001056358","primary_entity_name":"MANNATECH INC"},"word_count":1519,"has_tables":true,"body_markdown":"mtex20260331_10q.htm\n\n0001056358\nMANNATECH INC\nfalse\n--12-31\nQ1\n2026\n627\n756\n\n0.01\n0.01\n1,000,000\n1,000,000\n0\n0\n0\n0\n0.0001\n0.0001\n99,000,000\n99,000,000\n2,742,857\n1,929,670\n2,742,857\n1,900,930\n813,187\n841,927\n3\n0.1\n0.1\n2.8\n0\n0\n0\n2\n3\n10\n5\n0.2\n5\n0.1\n0.1\nhttp://www.mannatech.com/20260331#PropertyPlantAndEquipmentWithConstructionInProgressNet\nhttp://www.mannatech.com/20260331#PropertyPlantAndEquipmentWithConstructionInProgressNet\n0\n1\n25\nfalse\nfalse\nfalse\nfalse\nNo material amounts were reclassified from accumulated other comprehensive loss.\n\n00010563582026-01-012026-03-31\nxbrli:shares\n00010563582026-05-05\nthunderdome:item\niso4217:USD\n00010563582026-03-31\n00010563582025-12-31\niso4217:USDxbrli:shares\n00010563582025-01-012025-03-31\n0001056358mtex:CommonStockOutstandingMember2025-12-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001056358us-gaap:RetainedEarningsMember2025-12-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31\n0001056358us-gaap:TreasuryStockCommonMember2025-12-31\n0001056358mtex:CommonStockOutstandingMember2026-01-012026-03-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001056358us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31\n0001056358us-gaap:TreasuryStockCommonMember2026-01-012026-03-31\n0001056358mtex:CommonStockOutstandingMember2026-03-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001056358us-gaap:RetainedEarningsMember2026-03-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31\n0001056358us-gaap:TreasuryStockCommonMember2026-03-31\n0001056358mtex:CommonStockOutstandingMember2024-12-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001056358us-gaap:RetainedEarningsMember2024-12-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31\n0001056358us-gaap:TreasuryStockCommonMember2024-12-31\n00010563582024-12-31\n0001056358mtex:CommonStockOutstandingMember2025-01-012025-03-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001056358us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31\n0001056358us-gaap:TreasuryStockCommonMember2025-01-012025-03-31\n0001056358mtex:CommonStockOutstandingMember2025-03-31\n0001056358us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001056358us-gaap:RetainedEarningsMember2025-03-31\n0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31\n0001056358us-gaap:TreasuryStockCommonMember2025-03-31\n00010563582025-03-31\nxbrli:pure\n0001056358us-gaap:OtherInvesteesMember2026-03-31\n0001056358us-gaap:OtherInvesteesMember2025-12-31\n0001056358mtex:LoyaltyProgramMember2026-03-31\n0001056358mtex:LoyaltyProgramMember2025-12-31\n0001056358us-gaap:SubsequentEventMember2026-04-012026-04-01\n0001056358srt:ScenarioForecastMember2026-04-022026-12-31\n0001056358mtex:JadeCapitalMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23\n0001056358mtex:JadeCapitalMembermtex:DebtInstrumentUnsecuredNotesPayableMember2026-03-31\n0001056358mtex:JStanleyFrederickMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23\n0001056358mtex:JStanleyFrederickMembermtex:DebtInstrumentUnsecuredNotesPayableMember2026-03-31\n0001056358mtex:KevinRobbinsMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23\n0001056358mtex:KevinRobbinsMembermtex:DebtInstrumentUnsecuredNotesPayableMember2026-03-31\n0001056358mtex:JadeCapitalMember2026-03-31\n0001056358mtex:JStanleyFrederickMember2026-03-31\n0001056358mtex:KevinRobbinsMember2026-03-31\n0001056358mtex:The2017StockIncentivePlanMember2017-04-17\n0001056358mtex:The2017StockIncentivePlanMember2026-03-31\nutr:Y\n0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMembersrt:MinimumMember2017-04-172017-04-17\n0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMembersrt:MaximumMember2017-04-172017-04-17\n0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMember2017-04-172017-04-17\n0001056358mtex:IncentiveOptionMembermtex:The2017StockIncentivePlanMember2017-04-172017-04-17\n0001056358mtex:SharebasedPaymentArrangementOptionTreasuryStockMembermtex:The2017StockIncentivePlanMember2026-01-012026-03-31\n0001056358mtex:SharebasedPaymentArrangementOptionTreasuryStockMembermtex:The2017StockIncentivePlanMember2025-01-012025-03-31\n0001056358us-gaap:RestrictedStockMember2026-03-102026-03-10\n0001056358us-gaap:RestrictedStockMember2026-03-10\n0001056358srt:ScenarioForecastMember2026-12-31\n0001056358srt:ScenarioForecastMember2027-12-31\n0001056358srt:ScenarioForecastMember2028-12-31\n0001056358srt:DirectorMember2026-01-012026-03-31\n0001056358srt:DirectorMember2025-01-012025-03-31\n0001056358us-gaap:AccumulatedTranslationAdjustmentMember2025-12-31\n0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-12-31\n0001056358us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-03-31\n0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-01-012026-03-31\n0001056358us-gaap:AccumulatedTranslationAdjustmentMember2026-03-31\n0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-03-31\n00010563582023-03-10\n0001056358us-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001056358us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001056358us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001056358us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001056358us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001056358us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001056358us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001056358us-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001056358us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2026-03-31\n0001056358us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2026-03-31\n0001056358us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-12-31\n0001056358us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-12-31\n0001056358us-gaap:OperatingSegmentsMember2026-01-012026-03-31\n0001056358us-gaap:OperatingSegmentsMember2025-01-012025-03-31\n0001056358us-gaap:MaterialReconcilingItemsMember2026-01-012026-03-31\n0001056358us-gaap:MaterialReconcilingItemsMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembermtex:AmericasOtherMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembermtex:AmericasOtherMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:CN2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:CN2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:KR2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:KR2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembermtex:AsiaPacificOtherMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembermtex:AsiaPacificOtherMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2025-01-012025-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-03-31\n0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-03-31\n0001056358us-gaap:ProductMember2026-01-012026-03-31\n0001056358us-gaap:ProductMember2025-01-012025-03-31\n0001056358mtex:AssociateServiceFeesMember2026-01-012026-03-31\n0001056358mtex:AssociateServiceFeesMember2025-01-012025-03-31\n0001056358us-gaap:ProductAndServiceOtherMember2026-01-012026-03-31\n0001056358us-gaap:ProductAndServiceOtherMember2025-01-012025-03-31\n0001056358srt:AmericasMember2026-03-31\n0001056358srt:AmericasMember2025-12-31\n0001056358srt:AsiaPacificMember2026-03-31\n0001056358srt:AsiaPacificMember2025-12-31\n0001056358us-gaap:EMEAMember2026-03-31\n0001056358us-gaap:EMEAMember2025-12-31\n\n \n\n \n\n[Table of Contents](#toc)\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\nWashington, D.C. 20549\n\n \n\n \n\n**FORM 10-Q**\n\n(Mark One)\n\n \n\n☒         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n**For the quarterly period ended:** **March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ___________ to ___________.\n\n \n\nCommission File No. 000-24657\n\n \n\n**MANNATECH, INCORPORATED**\n\n \n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n**Texas**\n\n**75-2508900**\n\n(State or other Jurisdiction of Incorporation or Organization)\n\n(I.R.S. Employer Identification No.)\n\n**1410 Lakeside Parkway, Suite 200,**\n \n\n**Flower Mound, Texas**\n\n**75028**\n\n(Address of Principal Executive Offices)\n\n(Zip Code)\n\n \n\nRegistrant’s Telephone Number, including Area Code: **(972) 471-7400**\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n Title of each class\n\n Trading Symbol(s)\n\n Name of each exchange on which registered\n\n Common Stock,  par value $0.0001 per share\n\n MTEX\n\n The Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n Large accelerated filer\n\n ☐\n\nAccelerated filer\n\n ☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging Growth Company\n\n☐\n\n \n\nIf an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\nYes ☐ No ☒\n\n \n\nAs of May 5, 2026, the number of shares outstanding of the registrant’s sole class of common stock, par value $0.0001 per share, was 1,929,670.\n\n \n\n \n\n[Table of Contents](#toc)\n\n    \n\n \n\n**MANNATECH, INCORPORATED**\n\n**TABLE OF CONTENTS**\n\n \n\n[Special Note Regarding Forward-Looking Statements](#special)\n\n[1](#special)\n\n**Part I**–** FINANCIAL INFORMATION**\n\n \n\n[Item 1. Financial Statements](#financialstmts)\n\n[2](#financialstmts)\n\n[Condensed Consolidated Balance Sheets (unaudited)](#bs)\n\n[2](#bs)\n\n[Condensed Consolidated Statements of Operations (unaudited)](#ops)\n\n[3](#ops)\n\n[Condensed Consolidated Statements of Comprehensive Loss (unaudited)](#comp)\n\n[4](#comp)\n\n[Condensed Consolidated Statements of Shareholders’ Equity (unaudited)](#equity)\n\n[5](#equity)\n\n[Condensed Consolidated Statements of Cash Flows (unaudited)](#cf)\n\n[6](#cf)\n\n[Notes to Condensed Consolidated Financial Statements (unaudited)](#notes)\n\n[8](#notes)\n\n \n \n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#mda)\n\n[24](#mda)\n\n[Company Overview](#companyoverview)\n\n[24](#companyoverview)\n\n[Results of Operations](#resultsofops)\n\n[25](#resultsofops)\n\n[Liquidity and Capital Resources](#liquidity)\n\n[31](#liquidity)\n\n[Significant Accounting Policies and Critical Estimates](#sigacctingcriticalestimates)\n\n[33](#sigacctingcriticalestimates)\n\n \n \n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#quant)\n\n[35](#quant)\n\n \n \n\n[Item 4. Controls and Procedures](#controls)\n\n[35](#controls)\n\n \n \n\n**Part II**–** OTHER INFORMATION**\n\n \n\n[Item 1. Legal Proceedings](#legal)\n\n[36](#legal)\n\n \n \n\n[Item 1A. Risk Factors](#risk)\n\n[36](#risk)\n\n \n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#unregistered)\n\n[36](#unregistered)\n\n \n \n\n[Item 3. Defaults Upon Senior Securities](#defaults)\n\n[36](#defaults)\n\n \n \n\n[Item 4. Mine Safety Disclosures](#mine)\n\n[36](#mine)\n\n \n \n\n[Item 5. Other Information](#otherinfo)\n\n[36](#otherinfo)\n\n \n \n\n[Item 6. Exhibits](#exhibits)\n\n[37](#exhibits)\n\n \n \n\n[Signatures](#signatures)\n\n[38](#signatures)\n\n \n\n \n\n[Table of Contents](#toc)\n\n    \n\n \n\n**Special Note Regarding Forward-Looking Statements**\n\n \n\nCertain disclosures and analyses in this Form 10-Q, including information incorporated by reference, may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995 that are subject to various risks and uncertainties. Opinions, forecasts, projections, guidance, or other statements other than statements of historical fact are considered forward-looking statements and reflect only current views about future events and financial performance. Some of these forward-looking statements include statements regarding:\n\n \n\n \n\n•\n\nmanagement’s plans and objectives for future operations;\n\n \n\n•\n\nexisting cash flows being adequate to fund future operational needs;\n\n \n\n•\n\nfuture plans related to budgets, future capital requirements, market share growth, and anticipated capital projects and obligations;\n\n \n\n•\n\nthe realization of net deferred tax assets;\n\n \n\n•\n\nthe ability to curtail operating expenditures;\n\n \n\n•\n\nglobal statutory tax rates remaining unchanged;\n\n \n\n•\n\nthe impact of future market changes due to exposure to foreign currency translations;\n\n \n\n•\n\nthe possibility of certain policies, procedures, and internal processes minimizing exposure to market risk;\n\n \n\n•\n\nthe impact of new accounting pronouncements on financial condition, results of operations, or cash flows;\n\n \n\n•\n\nthe outcome of new or existing litigation matters;\n\n \n\n•\n\nthe outcome of new or existing regulatory inquiries or investigations;\n\n \n\n•\n\nother assumptions described in this report underlying such forward-looking statements.\n\n \n\nAlthough we believe that the expectations included in these forward-looking statements are reasonable, these forward-looking statements are subject to certain events, risks, assumptions, and uncertainties, including those discussed below, the “Risk Factors” section in Part I, Item 1A of our Form 10-K for the year ended December 31, 2025, and elsewhere in this Form 10-Q and the documents incorporated by reference herein. If one or more of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results and developments could materially differ from those expressed in or implied by such forward-looking statements. For example, any of the following factors could cause actual results to vary materially from our projections:\n\n \n\n \n\n•\n\noverall growth or lack of growth in the nutritional supplements industry;\n\n \n\n•\n\nplans for expected future product development;\n\n \n\n•\n\nchanges in manufacturing costs;\n\n \n\n•\n\nshifts in the mix of packs and products;\n\n \n\n•\n\nthe future impact of any changes to global associate career and compensation plans or incentives or the regulations governing such plans and incentives;\n\n \n\n•\n\nthe ability to attract and retain independent associates and preferred customers;\n\n \n\n•\n\nnew regulatory changes that may affect operations, products or compensation plans and incentives;\n\n \n\n•\n\nability of our outside suppliers and manufacturers to supply products in sufficient quantities and comply with our product safety and quality standards or applicable law;\n\n \n\n•\n\nthe competitive nature of our business with respect to products and pricing;\n\n \n\n•\n\npublicity related to our products or network marketing; and\n\n \n\n•\n\nthe political, social and economic climate of the countries in which we operate; and\n\n \n\n•\n\nchanges in trade policy in the United States and other countries, including the imposition of tariffs and the resulting consequences, may adversely impact our business, results of operations and financial condition.\n\n \n\nForward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “hopes,” “potential,” and “continues” or other similar words or the negative of such terms and other comparable terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. Readers are cautioned when considering these forward-looking statements to keep in mind these risks, assumptions, and uncertainties and any other cautionary statements in this report, as all of the forward-looking statements contained herein speak only as of the date of this report.\n\n \n\nUnless stated otherwise, all financial information throughout this report and in the Condensed Consolidated Financial Statements and related Notes include Mannatech, Incorporated and all of its subsidiaries on a consolidated basis and may be referred to herein as “Mannatech,” “the Company,” “its,” “we,” “us,” “our,” or “their.”\n\n \n\nOur products are not intended to diagnose, cure, treat, or prevent any disease, and any statements about our products contained in this report have not been evaluated by the Food and Drug Administration, also referred to herein as the “FDA.”\n\n \n\n \n\n1\n\n[Table of Contents](#toc)\n\n \n\n \n\n**PART I**–**FINANCIAL INFORMATION**"}